title: Factors influencing preclinical in vivo evaluation of mumps vaccine strain immunogenicity.
abstract: Immunogenicity testing in animals is a necessary preclinical assay for demonstration of vaccine efficacy the results of which are often the basis for the decision whether to proceed or withdraw the further development of the novel vaccine candidate. However, in vivo assays are rarely, if at all, optimized and validated. Here we clearly demonstrate the importance of in vivo assay (mumps virus immunogenicity testing in guinea pigs) optimization for gaining reliable results and the suitability of Fractional factorial design of experiments (DoE) for such a purpose. By the use of DoE with resolution IV (2IV((4-1))) we clearly revealed that the parameters significantly increasing assay sensitivity were interval between animal immunizations followed by the body weight of experimental animals. The quantity (0 versus 2%) of the stabilizer (fetal bovine serum, FBS) in the sample was shown as non-influencing parameter in DoE setup. However, the separate experiment investigating only the FBS influence, and performed under other parameters optimally set, showed that FBS also influences the results of immunogenicity assay. Such finding indicated that (a) factors with strong influence on the measured outcome can hide the effects of parameters with modest/low influence and (b) the matrix of mumps virus samples to be compared for immunogenicity must be identical for reliable virus immunogenicity comparison. Finally the 3 mumps vaccine strains widely used for decades in the licensed vaccines were for the first time compared in an animal model, and results obtained were in line with their reported immunogenicity in human population supporting the predictive power of the optimized in vivo assay.
authors.affiliation: a University of Zagreb; Center for Research and Knowledge Transfer in Biotechnology ; Zagreb , Croatia.|b Center of Excellence for Viral Immunology and Vaccines ; CERVirVac; Zagreb , Croatia.
authors.forename: B
authors.initials: B
authors.lastname: Halassy
authors.affiliation: a University of Zagreb; Center for Research and Knowledge Transfer in Biotechnology ; Zagreb , Croatia.|b Center of Excellence for Viral Immunology and Vaccines ; CERVirVac; Zagreb , Croatia.
authors.forename: T
authors.initials: T
authors.lastname: Kurtović
authors.affiliation: a University of Zagreb; Center for Research and Knowledge Transfer in Biotechnology ; Zagreb , Croatia.|b Center of Excellence for Viral Immunology and Vaccines ; CERVirVac; Zagreb , Croatia.
authors.forename: M
authors.initials: M
authors.lastname: Brgles
authors.affiliation: c Institute of Immunology Inc.; Quality Control Department ; Zagreb , Croatia.
authors.forename: M
authors.initials: M
authors.lastname: Lang Balija
authors.affiliation: a University of Zagreb; Center for Research and Knowledge Transfer in Biotechnology ; Zagreb , Croatia.|b Center of Excellence for Viral Immunology and Vaccines ; CERVirVac; Zagreb , Croatia.
authors.forename: D
authors.initials: D
authors.lastname: Forčić
mesh_terms: D032761:Animal Experimentation / Q000592:standards*; D000818:Animals; D001835:Body Weight; D004353:Drug Evaluation, Preclinical / Q000379:methods* / Q000592:standards*; D005260:Female; D006168:Guinea Pigs; D007115:Immunization Schedule; D009108:Mumps Vaccine / Q000008:administration & dosage / Q000276:immunology*; D009109:Mumps virus / Q000276:immunology*; D012107:Research Design; D016896:Treatment Outcome
chemical_list: D009108:Mumps Vaccine
keywords: design of Experiments (DoE); in vivo bioassay optimization; mumps virus; non-clinical vaccine immunogenicity assessment